Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: a systematic review

KI Notarte, I Guerrero‐Arguero… - Journal of medical …, 2022 - Wiley Online Library
Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (COVID‐19)(severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) …
被引用次数：115 相关文章
[PDF] archive.org

[PDF][PDF] Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review

BM Henry - scholar.archive.org
2019 (COVID-19) mRNA vaccines such as Pfizer-BioNTech (mRNA BNT161b2) and
Moderna (mRNA-1273) in preventing breakthrough infections due to diminishing humoral …
[PDF] academia.edu

[PDF][PDF] Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review

BM Henry - academia.edu
2019 (COVID-19) mRNA vaccines such as Pfizer-BioNTech (mRNA BNT161b2) and
Moderna (mRNA-1273) in preventing breakthrough infections due to diminishing humoral …
[HTML] nih.gov

[HTML][HTML] Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review

KI Notarte, I Guerrero‐Arguero, JV Velasco… - Journal of Medical …, 2022 - ncbi.nlm.nih.gov
Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (COVID‐19)(severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) …

Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a systematic review.

KI Notarte, I Guerrero-Arguero, JV Velasco, AT Ver… - 2022 - cabidigitallibrary.org
Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (COVID-19)(severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) …

Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review

KI Notarte, I Guerrero‐arguero, JV Velasco… - JOURNAL OF …, 2022 - iris.univr.it
Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (SARS-CoV-2) mRNA vaccines such as Pfizer-BioNTech (mRNA BNT161b2) and …

Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review

KI Notarte, I Guerrero-Arguero, JV Velasco, AT Ver… - medRxiv, 2021 - medrxiv.org
Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (COVID-19) mRNA vaccines such as Pfizer-BioNTech (mRNA BNT161b2) and …

Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review.

KI Notarte, I Guerrero‐Arguero… - Journal of Medical …, 2022 - search.ebscohost.com
Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (COVID‐19)(severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) …

Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review

KI Notarte, I Guerrero-Arguero… - Journal of medical …, 2022 - pubmed.ncbi.nlm.nih.gov
Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (COVID-19)(severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) …
[HTML] europepmc.org

[HTML][HTML] Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review

KI Notarte, I Guerrero-Arguero, JV Velasco, AT Ver… - 2021 - europepmc.org
Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (COVID-19) mRNA vaccines such as Pfizer-BioNTech (mRNA BNT161b2) and …